Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia (Q31886533)

4 July 2017

title

Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia (English)

1 reference

4 July 2017

1 reference

1 reference

Giral P

1

1 reference

4 July 2017

Bruckert E

2

1 reference

4 July 2017

Jacob N

3

1 reference

4 July 2017

Chapman MJ

4

1 reference

4 July 2017

Foglietti MJ

5

1 reference

4 July 2017

Turpin G

6

1 reference

4 July 2017

language of work or name

1 reference

1 February 2001

1 reference

4 July 2017

1 reference

4 July 2017

volume

154

1 reference

4 July 2017

issue

2

1 reference

4 July 2017

page(s)

421-427

1 reference

Plasma homocyst(e)ine levels in men with premature coronary artery disease

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Fish oil decreases serum homocysteine in hyperlipemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Lipid-lowering drugs and homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Serum total homocysteine and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Cysteine is a cardiovascular risk factor in hyperlipidemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Correlates of plasma total homocysteine in patients with hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Labile methyl balances for normal humans on various dietary regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Determinants of hyperhomocysteinemia: a matter of nature and nurture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Uricosuric effect of fenofibrate in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900474-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(00)00474-3

1 reference

4 July 2017

1 reference